Belgian guidelines concerning central neural blockade in patients with drug-induced alteration of coagulation: An Update

Acta Anaesthesiologica Belgica

Volumn 56, Issue 2, 2005, Pages 139-146

  Vandermeulen, E ^a   Singelyn, F ^b   Vercauteren, M ^c   Brichant, J F ^d   Ickx, B E ^e   Gautier, P ^f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

^e ERASME HOSPITAL   (Belgium)

^f Ste Anne St Remi Hospital   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID CALCIUM; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALTEPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; CALPARINE; CARDIOASPIRINE; CARDIPHAR; CLOPIDOGREL; CORONAIR; DALTEPARIN; DEXTRAN; DIPYRIDAMOLE; DIPYRIDAMOLE EG; DIPYRIDAMOLE TEVA; DOCDIPYRI; ENOXAPARIN; EPTIFIBATIDE; EXANTHA; FIBRINOLYTIC AGENT; FONDAPARINUX; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HEPARIN; HEPARINE LEO; HEPARINE SODIQUE; LEPIRUDIN; LOCAL ANESTHETIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; LYSINE ACETYLSALICYLATE; NADROPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENPROCOUMON; RETEPLASE; SEDERGINE; STEROID; STREPTOKINASE; TAMPYRINE; TENECTEPLASE; THROMBIN INHIBITOR; TICLOPIDIN RATIOPHARM; TICLOPIDINE; TICLOPIDINE EG; TICLOPIDINE TEVA; TINZAPARIN; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UROKINASE CHOAY; WARFARIN;

ANALGESIA; ANESTHESIA; ANESTHESIOLOGICAL TECHNIQUES; ANTICOAGULATION; BELGIUM; BLEEDING; BLOOD CLOTTING; DRUG SAFETY; EPIDURAL ANESTHESIA; HUMAN; NERVE BLOCK; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SPINAL ANESTHESIA; SPINAL CORD HEMORRHAGE; THROMBOCYTOPENIA; THROMBOSIS; THROMBOSIS PREVENTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; BELGIUM; FACTOR X; FIBRINOLYTIC AGENTS; HEMATOMA; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NERVE BLOCK; PLATELET AGGREGATION INHIBITORS; THROMBIN; THROMBOSIS; VITAMIN K;

EID: 21744460962     PISSN: 00015164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Anonymous, Belgian guidelines concerning drug induced alteration of coagulation and central neuraxial anesthesia, ACTA ANAESTHESIOLOGICA BELGICA, 51, 101-104, 2000.
2. Vandermeulen E. P., Van Aken H., Vermylen J., Anticoagulants and spinal-epidural anesthesia, ANESTH. ANALG., 79, 1165-1177, 1994.
3. Horlocker T. T., Wedel D. J., Neurologic complications of spinal and epidural anesthesia, REG. ANESTH. PAIN MED., 25, 83-98, 2000.
4. Schroeder D. R., Statistics: detecting a rare adverse drug reaction using spontaneous reports, REG. ANESTH. PAIN MED., 1998, 23, 183-189.
5. Lawton M. T., Porter R. W., Heiserman J. E., et al., Surgical management of spinal epidural hematoma: relationship between surgical timing and neurological outcome, J. NEUROSURG., 83, 1-7, 1995.
6. Raskob G. E., Hirsh J., Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery, CHEST, 124, 379S-385S, 2003.
7. Zufferey P., Laporte S., Quenet S., et al., Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials, THROMB. HAEMOST., 90, 654-661, 2003.
8. Hull R. D., Pineo G. R, Stein P. D., et al., Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review, ARCH. INTERN. MED., 161, 1952-1960, 2001.
9. Geerts W. H., Pineo G. P., Heit J. A., et al., Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, CHEST, 126, 338S-400S, 2004.
10. Kehlet H., Holte K., Effect of postoperative analgesia on surgical outcome, BR. J. ANAESTH., 87, 62-72, 2001.
11. Rodgers A., Walker N., Schug S., et al., Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials, BMJ, 321, 1493-1497, 2000.
12. Modig J., Borg T., Karlstrom G., et al., Thromboembolism after total hip replacement: role of epidural and general anesthesia, ANESTH. ANALG., 62, 174-180, 1983.
13. Prins M. H., Hirsh J., A comparison of general anesthesia and regional anesthesia as a risk factor for deep vein thrombosis following hip surgery: a critical review, THROMB. HAEMOST., 64, 497-500, 1990.
14. Horlocker T. T., Wedel D. J., Benzon H., et al., Regional anesthesia in the anticoagulated patient: defining the risks, REG. ANESTH. PAIN MED., 29, 1-12, 2004.
15. Harenberg J., Jorg I., Fenyvesi T, Heparin-induced thrombocytopenia: pathophysiology and new treatment options, PATHOPHYSIOL. HAEMOST. THROMB., 32, 289-294, 2002.
16. Sanofi-Synthelabo, Organon N. Org31540/SR90107A. Clinical Investigator Brochure.
17. Boneu B., Necciari J., Cariou R., et al., Pharmacokinetics and tolerance of the natural pentasaccharide (SR90I07/Org3I540) with high affinity to antithrombin III in man, THROMB. HAEMOST., 74, 1468-1473, 1995.
18. Kwong L. M., Muntz J. E., Thromboprophylaxis dosing: the relationship between timing of first administration, efficacy, and safety, AM. J. ORTHOP., 31, 16-20, 2002.
19. Horlocker T. T., Wedel D. J., Benzon H., et al., Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation), REG. ANESTH. PAIN MED., 28, 172-197, 2003.
20. Leese P. T., Hubbard R. C., Karim A., et al., Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial, J. CLIN. PHARMACOL., 40, 124-132, 2000.
21. Steinhubl S. R., Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists, CORON. ARTERY DIS., 14, 381-386, 2003.
22. Wheeler G. L., Braden G. A., Steinhubl S. R., et al., The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy, AM. HEART. J., 143, 602-611, 2002.
23. Dasgupta H., Blankenship J. C., Wood G. C., et al., Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis, AM. HEART. J., 140, 206-211, 2000.
24. Huang F., Hong E., Platelet glycoprotein IIb/IIIa inhibition and its clinical use, CURR. MED. CHEM. CARDIOVASC. HEMATOL. AGENTS, 2, 187-196, 2004.
25. Rosove M. H., Platelet glycoprotein IIb/IIIa inhibitors, BEST. PRACT. RES. CLIN. HAEMATOL., 17, 65-76, 2004.
26. Nowak G., The ecarin clotting time, a universal method to quantify direct thrombin inhibitors, PATHOPHYSIOL. HAEMOST. THROMB., 33, 173-183, 2003.
27. Gosselin R. C., King J. H., Janatpour K. A., et al., Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing, ANN. PHARMACOTHER., 38, 1383-1388, 2004.